Literature DB >> 1662567

Association between hepatitis C virus and mixed cryoglobulinemia [see comment].

C Ferri1, F Greco, G Longombardo, P Palla, A Moretti, E Marzo, A Mazzoni, G Pasero, S Bombardieri, P Highfield.   

Abstract

The prevalence of hepatitis C virus (HCV) RNA and of antibodies to HCV in an unselected series of 42 mixed cryoglobulinemia patients was investigated in this study. HCV RNA was detected by the polymerase chain reaction technique, and HCV antibodies by two enzyme-linked immunosorbent assays (Chiron ELISA HCV, Second Generation, Emeryville CA, USA; Wellcome Diagnostic, England). HCV RNA was found in 86% of the mixed cryoglobulinemia patients. Using either the Chiron ELISA or the Wellcome ELISA, HCV antibodies were present in 90% of the same samples; anti-HCVAb seropositivity was confirmed in all cases by immunoblot assay (Chiron RIBA HCV, Second Generation Assay). A striking correlation between HCV RNA and anti-HCV antibody seropositivities was recorded. HCV RNA in mixed cryoglobulinemia patients was not correlated with the presence or absence of biopsy-proven liver involvement. These results suggest that the association between HCV and mixed cryoglobulinemia is not fortuitous, and therefore that HCV may have an etiopathogenetic role in this disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662567

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  46 in total

Review 1.  Mechanisms of viral pathogenesis in rheumatic disease.

Authors:  A Perl
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

Review 2.  Hepatitis C virus infection and lymphoproliferative disorders.

Authors:  L R Peña; S Nand; N De Maria; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

3.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Hepatitis C: a possible etiology for cryoglobulinaemia type II.

Authors:  A Pechère-Bertschi; L Perrin; P de Saussure; J J Widmann; E Giostra; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

5.  Is interferon alpha 2b effective on cryoglobulinaemia related to hepatitis C virus?

Authors:  B Taillan; E Ferrari; A Pesce; G Garnier; H Vinti; J G Fuzibet; P Dujardin
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

Review 6.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 7.  Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia.

Authors:  Merav Lidar; Noga Lipschitz; Nancy Agmon-Levin; Pnina Langevitz; Ori Barzilai; Maya Ram; Bat-Sheba Porat-Katz; Nicola Bizzaro; Jan Damoiseaux; Jan Willem Cohen Tervaert; Salvatore deVita; Stefano Bombardieri; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

8.  Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.

Authors:  C Ferri; A L Zignego; G Longombardo; M Monti; L La Civita; F Lombardini; F Greco; A Mazzoni; G Pasero; P Gentilini
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

9.  B cell non-Hodgkin's lymphoma in chronic hepatitis C virus patients: An interesting relationship.

Authors:  Hassan S Hamdy; Nadia A Abdelkader; Amal Mansour; Enas H Allam; Hisham M El-Wakiel; Dina Elshenawy
Journal:  Indian J Gastroenterol       Date:  2015-04-29

10.  Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia.

Authors:  A Gabrielli; A Manzin; M Candela; M L Caniglia; S Paolucci; M G Danieli; M Clementi
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.